KOR

e-Article

Infection Risk and Use of Prophylaxis with Anti-BCMA Bispecific T Cell Engagers and Belantamab Mafodotin for Patients with Relapsed and Refractory Multiple Myeloma
Document Type
Journal
Source
BLOOD; NOV 2 2023, 142 4p. Supplement: 1
Subject
Language
English
ISSN
15280020